|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Intraductal neoplasm of the intrahepatic bile duct: Clinicopathological study of 24 cases显示文摘AIM: To investigate the clinicopathological features of intraductal neoplasm of the intrahepatic bile duct (INihB). METHODS: Clinicopathological features of 24 cases of INihB, which were previously diagnosed as biliary papillomatosis or intraductal growth of intrahepatic biliary neoplasm, were reviewed. Mucin immunohistochemistry was performed for mucin (MUC)1, MUC2, MUC5AC and MUC6. Ki-67, P53 and β-catenin immunoreactivity were also examined. We categorized each tumor as adenoma (low grade), borderline (intermediate grade), and malignant (carcinoma in situ , high grade including tumors with microinvasion). RESULTS: Among 24 cases of INihB, we identified 24 tumors. Twenty of 24 tumors (83%) were composed of a papillary structure; the same feature observed in intraductal papillary neoplasm of the bile duct (IPNB). In contrast, the remaining four tumors (17%) showed both tubular and papillary structures. In three of the four tumors (75%), macroscopic mucin secretion was limited but microscopic intracellular mucin was evident. Histologically, 16 tumors (67%) were malignant, three (12%) were borderline, and five (21%) were adenoma. Microinvasion was found in four cases (17%). Immunohistochemical analysis revealed that MUC1 was not expressed in the borderline/adenoma group but was expressed only in malignant lesions (P = 0.0095). Ki-67 labeling index (LI) was significantly higher in the malignant group than in the borderline/adenoma group (22.2 ± 15.5 vs 7.5 ± 6.3, P < 0.01). In the 16 malignant cases, expression of MUC5AC showed borderline significant association with high Ki-67 LI (P = 0.0622). Nuclear expression of β-catenin was observed in two (8%) of the 24 tumors, and these two tumors also showed MUC1 expression. P53 was negative in all tumors. CONCLUSION: Some cases of INihB have a tubular structure, and are subcategorized as IPNB with tubular structure. MUC1 expression in INihB correlates positively with degree of malignancy. | Yoshiki Naito Hironori Kusano Osamu Nakashima Eiji Sadashima Satoshi Hattori Tomoki Taira Akihiko Kawahara Yoshinobu Okabe Kazuhide Shimamatsu Jun Taguchi Seiya Momosaki Koji Irie Rin Yamaguchi Hiroshi Yokomizo Michiko Nagamine Seiji Fukuda Shinichi Sugiyama Naoyo Nishida Koichi Higaki Munehiro Yoshitomi Masafumi Yasunaga Koji Okuda Hisafumi Kinoshita Masayoshi Kage Masamichi Nakayama Makiko Yasumoto Jun Akiba Hirohisa Yano | 2012 | World Journal of Gastroenterology2012，18，28： | 16 |
| 2 | Decreased protein C activation is associated with abnormal collagen turnover in the intraalveolar space of patients with interstitial lung disease显示文摘 | Hiroki Yasui Habazza E C Osamu Taguchi | 2000 | Clin Appl Thrombosis Hemostasis2000，6，： | 1 |
| 3 | Protein C anticoagulant system in patients with interstitial lung disease显示文摘 | Hiroyasu Kobayashi Gabazza E C Osamu Taguchi | 1998 | Am J Respir Crit Care Med1998，157，： | 1 |
| 4 | Recombinant human interleukin-11 improved carboplatin-induced thrombocytopenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells显示文摘 | Minori Saitoh Katsunari Taguchi Kazuhiro Momose Kazutaka Suga Noriyuki Yamazaki Chizuko Ono Tatsuo Suzuki Osamu Takeuchi Shuhei Yasuda Keiji Miyata | 2001 | Cancer Chemotherapy and Pharmacology2001，，2： | 1 |
| 5 | Japanese Orthopaedic Association Cervical Myelopathy Evaluation Questionnaire (JOACMEQ): part 4. Establishment of equations for severity scores显示文摘 | Mitsuru Fukui Kazuhiro Chiba Mamoru Kawakami Shinichi Kikuchi Shinichi Konno Masabumi Miyamoto Atsushi Seichi Tadashi Shimamura Osamu Shirado Toshihiko Taguchi Kazuhisa Takahashi Katsushi Takeshita Toshikazu Tani Yoshiaki Toyama Kazuo Yonenobu Eiji Wada T | 2008 | Journal of Orthopaedic Science2008，，1： | 1 |
| 6 | An outcome measure for patients with cervical myelopathy: Japanese Orthopaedic Association Cervical Myelopathy Evaluation Questionnaire (JOACMEQ): Part 1显示文摘 | Mitsuru Fukui Kazuhiro Chiba Mamoru Kawakami Shin-ichi Kikuchi Shin-ichi Konno Masabumi Miyamoto Atsushi Seichi Tadashi Shimamura Osamu Shirado Toshihiko Taguchi Kazuhisa Takahashi Katsushi Takeshita Toshikazu Tani Yoshiaki Toyama Eiji Wada Kazuo Yonenobu | 2007 | Journal of Orthopaedic Science2007，，3： | 1 |
| 7 | Surgical strategies for unresectable hepatoblastomas显示文摘 | Tatsuro Tajiri Osamu Kimura Shigehisa Fumino Taizo Furukawa Tomoko Iehara Ryota Souzaki Yoshiaki Kinoshita Yuhki Koga Aiko Suminoe Toshiro Hara Kenichi Kohashi Yoshinao Oda Tomoro Hishiki Hajime Hosoi Eiso Hiyama Tomoaki Taguchi | 2012 | Journal of Pediatric Surgery2012，，12： | 1 |
| 8 | Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin显示文摘 | Keiichi Kontani Osamu Taguchi Yoshitomo Ozaki Jun Hanaoka Satoru Sawai Shuhei Inoue Hajime Abe Kazuyoshi Hanasawa Shozo Fujino | 2003 | International Journal of Molecular Medicine2003，，4： | 1 |
| 9 | Evaluating Prothrombotic state in lung cancer using molecular markers显示文摘 | Esteban C Gabazza Osamu Taguchi Tomoya Yamakami | 1993 | Chest1993，103，1： | 1 |
| 10 | Dynamic contrast-enhanced perfusion MR imaging of diseased vertebrae: analysis of three parameters and the distribution of the time-intensity curve patterns显示文摘 | Osamu Tokuda Noriko Hayashi Koutarou Taguchi Naofumi Matsunaga | 2005 | Skeletal Radiology2005，，10： | 1 |
| 11 | Role of Thrombin-Activatable Fibrinolysis Inhibitor in Allergic Bronchial Asthma显示文摘 | Atsushi Fujiwara Osamu Taguchi Takehiro Takagi Corina D'Alessandro-Gabazza Daniel Boveda-Ruiz Masaaki Toda Atsushi Yasukawa Yuki Matsushima Yasushi Miyake Hiroyasu Kobayashi Tetsu Kobayashi Paloma Gil-Bernabe Masahiro Naito Masamichi Yoshida John Morser Y | 2012 | Lung2012，，2： | 1 |
| 12 | Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture显示文摘BACKGROUND Angiogenesis inhibitors(AIs)combination with cytotoxic chemotherapy is a promising treatment for patients with colorectal cancer(CRC).Aflibercept(AFL)is an option for second-line treatment of CRC,according to the‘VELOUR’trial.Currently,we can choose from three AIs,including bevacizumab,ramucirumab,and AFL.Different AIs can be used in subsequent treatment because of their distinctive mechanisms of action.We addressed the uncertainty regarding AFL efficacy and safety in heavily-treated patients by comparing outcomes of survival treatment with second-line treatment.AIM To determine and compare the efficacy and safety profiles of AFL in the secondline and salvage therapy settings.METHODS Clinical data of 41 patients with advanced CRC who received intravenous AFL combined with the folinic acid-fluorouracil-irinotecan(FOLFIRI)regimen were collected retrospectively from six institutions in Japan,for the period from May 2017 to March 2019.Patient characteristics collected included age,sex,tumor location,RAS and RAF status,metastatic sites,number of previous treatment cycles,therapeutic response,adverse events,duration of previous AI treatment,and survival time.The end points were time to AFL treatment failure(aTTF)and median survival time post-AFL(aMST).Statistical analyses were performed to compare the efficacy and safety in the second-line setting with those of the salvage therapy setting,which was defined as the days since the end of secondline therapy.RESULTS All 41 patients who received AFL+FOLFIRI for advanced CRC had metastatic or unresectable cancer.Twenty-two patients received AFL in the second-line setting and nineteen in the salvage therapy setting.The patient characteristics were similar in the two groups,except for two factors.The median duration of the previous AI administration was shorter in the second-line patients compared with that in the salvage therapy patients(144 d vs 323 d,P=0.006).In the second-line and salvage therapy groups,the objective response rates were 11%and 0%,respectively(P=0.50),and the disease control rates were 53%and 50%,respectively(P=1.00).In the second-line and salvage therapy groups,the aTTF(123 d vs 71 d,respectively),aMST(673 d vs 396 d,respectively),and incidence of adverse events of grade 3[8(36%)vs 9(47%)]were not significantly different between the two groups.CONCLUSION AFL can be used to treat advanced CRC patients,with a similar safety and efficacy in the salvage therapy setting as in the second-line setting. | Taichi Yoshida Kentaro Takahashi Kengo Shibuya Osamu Muto Yuko Yoshida Daiki Taguchi Kazuhiro Shimazu Koji Fukuda Fuminori Ono Kyoko Nomura Hiroyuki Shibata | 2021 | World Journal of Gastrointestinal Oncology2021，13，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员